Samsung Biologics Wins Sustainability Leadership Award at 2026 CDMO Awards

Event summary

  • Samsung Biologics received the Sustainability Leadership Award at the 2026 CDMO Leadership Awards, recognizing its efforts in advancing sustainable practices across operations and value chain.
  • The company was also named 'Best in Class' in Cultural Fit in the 'Biologics—Large CDMOs' category, reflecting strong collaborative partnerships.
  • Samsung Biologics achieved a Platinum rating from EcoVadis and implemented an independently validated product carbon footprint (PCF) system.
  • The company plans to close the acquisition of a manufacturing facility in Rockville, Maryland, U.S., adding 60,000 liters of biomanufacturing capacity by the end of Q1 2026.

The big picture

Samsung Biologics' recognition at the 2026 CDMO Leadership Awards underscores the growing importance of sustainability in the contract manufacturing sector. As biopharmaceutical companies face increasing pressure to reduce their environmental impact, Samsung Biologics' commitment to sustainable practices positions it as a leader in the industry. The company's expansion plans, including the acquisition of the Rockville facility and the development of Bio Campus III, reflect its strategic focus on supporting next-generation therapies and emerging modalities.

What we're watching

Sustainability Integration
How Samsung Biologics will sustain its decarbonization efforts and resilient value chains in collaboration with global suppliers.
Capacity Expansion
The pace at which Samsung Biologics can integrate and utilize the additional 60,000 liters of biomanufacturing capacity from the Rockville facility.
Client Alignment
Whether Samsung Biologics can maintain its strong cultural fit and collaborative partnerships as it scales operations.